

## Memorandum # 1660-08

## MEMORANDUM

To: All Members, Member Organizations and ROPs

Date: September 19, 2008

Re: Withdrawal of Approval of Certain Underlying Securities or Options

Pursuant to Exchange Rule 1010 .02, The Philadelphia Stock Exchange, Inc. (The Exchange) has determined that the following common stocks no longer meet the current requirements necessary to maintain approval as securities underlying listed options, and that the last remaining option series **will expire at the close of business today**.

Introgen Therapeutics, Inc. (INGN/IUZ) iPass, Inc. (IPAS/QZQ)
NexCen Brands, Inc. (NEXC/QNL)
U.S. Gold Corporation (UXG)

Pursuant to Exchange Rule 1010 .01, The Exchange has determined that due to certain corporate actions the following common stocks no longer meet the current requirements necessary to maintain approval as securities underlying listed options. Therefore, the Exchange will not open any additional option series, and notes that the last remaining adjusted option series will expire on the date(s) below.

FTD Group (FTD) March 16, 2009
Genitope Corp. (GTOP/ ZKH/ LPD) January 19, 2010
Nymex Holdings, Inc. (NMX/ NJE, NJF, LON) January 19, 2009
Sonus Pharmaceuticals (SNUS/ NUY) January 19, 2009

Further, the Exchange requests that member organizations advise their customers of this announcement before entering option orders for customer accounts in the above noted issues.

Questions concerning this memorandum may be directed to Listings Administration at 1-800-the PHLX, choice #2 or Jessica Cooke at (215) 496-1496.